莫西沙星与雷贝拉唑治疗幽门螺杆菌阳性复发性十二指肠球部溃疡的研究

目的探讨莫西沙星与雷贝拉唑治疗幽门螺杆菌（HP）阳性复发性十二指肠球部溃疡的疗效。方法将92例经内镜诊断并检测证实HP阳性的十二指肠球部溃疡患者随机分为两组,治疗组49例,给予莫西沙星0.4,1次/d,共10 d;雷贝拉唑10 mg,2次/d,共42 d;对照组43例,给予克拉霉素500 mg,阿莫西林500 mg,2次/d,共10 d,雷贝拉唑10 mg,2次/d,共42 d;疗程结束4周后复查胃镜并检测HP,观察溃疡愈合,HP根除率,用药后的不良反应及溃疡复发率。结果治疗组和对照组溃疡总有效率分别为91.8%和86.0%,差异无统计学意义（P〉0.05）,治疗组和对照组HP根除率分别为93.9%和81.4%,差异有统计学意义（P〈0.05）,两组服药后不良反应少,有较好的安全性。治疗组及对照组半年及一年溃疡复发率分别为4.1%、11.6%和6.1%、18.6%,有显著性差异（P〈0.05）。结论莫西沙星,雷贝拉唑治疗HP阳性复发性十二指肠球部溃疡安全有效,HP根除率、溃疡复发率优于克拉霉素、阿莫西林及雷贝拉唑疗法。

Clinical Study of Kelameisu and Leibeilazuo on Patients with Helicobacter Pylori Infection of Relapse of Duodenal Ulcer

Objective To investigate the effect of moxishaxing and leibeilazuo therapy for helicobactor pylori（HP） infection of relapse in duodenal ulcer patients.Methods 92 cases with duodanl ulcer of relapse of Hp infection were divided into two groups at random.Treatment group（49cases）treated with moxishaxing（40mg） one daily,The treatment lasted course for 10 days and leibeilazuo（10mg） twice daily.The trcatment lasted course for 42 days.While the patients in the control group（43cases） were treated by kelameisu 0.5 with Amoxilin 0.5 twice daily,The treatment lasted course for 10 days and leibeilazuo（10mg） twice daily.The trcatment lasted course for 42 days.After one month by examination was Hp and endoscopy,which ulcer healing rate and eradication rate of Hp as well as effects of the medication were evaluatcd and compared.Results Ulcer healing rate were 91.9% and eradication rate of Hp were 93.9% in the treated group.While Ulcer healing rate were 86.1% and eradication rate of Hp were 81.4% in the control group.After their half-year relapse rate were 4.1% and 11.6%,After their one year relapse rate were 6.1% and 18.6%.There were no significant differences between the two groups respectivel.Conclusion moxishaxing and leibeilazuo therapy may effectively eradicate Hp infection and promote duodanl ulcer healing good than kelameisu and Amoxilin with leibeilazuo therapy.Without obviously adverse effect.